JP2020531525A - Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍−関連抗原に結合するタンパク質 - Google Patents

Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍−関連抗原に結合するタンパク質 Download PDF

Info

Publication number
JP2020531525A
JP2020531525A JP2020511319A JP2020511319A JP2020531525A JP 2020531525 A JP2020531525 A JP 2020531525A JP 2020511319 A JP2020511319 A JP 2020511319A JP 2020511319 A JP2020511319 A JP 2020511319A JP 2020531525 A JP2020531525 A JP 2020531525A
Authority
JP
Japan
Prior art keywords
seq
binding site
antigen
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2020511319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531525A5 (enExample
Inventor
グレゴリー ピー． チャン，
グレゴリー ピー． チャン，
アン エフ． チュン，
アン エフ． チュン，
ウィリアム ヘイニー，
ウィリアム ヘイニー，
ブラッドリー エム． ランディ，
ブラッドリー エム． ランディ，
ビアンカ プリンツ，
ビアンカ プリンツ，
ニコライ ワグトマン，
ニコライ ワグトマン，
ジンヤン ドゥ，
ジンヤン ドゥ，
Original Assignee
ドラゴンフライ セラピューティクス， インコーポレイテッド
ドラゴンフライ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドラゴンフライ セラピューティクス， インコーポレイテッド, ドラゴンフライ セラピューティクス， インコーポレイテッド filed Critical ドラゴンフライ セラピューティクス， インコーポレイテッド
Publication of JP2020531525A publication Critical patent/JP2020531525A/ja
Publication of JP2020531525A5 publication Critical patent/JP2020531525A5/ja
Priority to JP2023027219A priority Critical patent/JP2023062184A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020511319A 2017-08-23 2018-08-23 Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍−関連抗原に結合するタンパク質 Ceased JP2020531525A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023027219A JP2023062184A (ja) 2017-08-23 2023-02-24 Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍－関連抗原に結合するタンパク質

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201762549201P 2017-08-23 2017-08-23
US62/549,201 2017-08-23
US201762558514P 2017-09-14 2017-09-14
US201762558510P 2017-09-14 2017-09-14
US201762558509P 2017-09-14 2017-09-14
US201762558511P 2017-09-14 2017-09-14
US62/558,514 2017-09-14
US62/558,510 2017-09-14
US62/558,511 2017-09-14
US62/558,509 2017-09-14
US201762566828P 2017-10-02 2017-10-02
US62/566,828 2017-10-02
US201762581357P 2017-11-03 2017-11-03
US62/581,357 2017-11-03
US201762608384P 2017-12-20 2017-12-20
US62/608,384 2017-12-20
PCT/US2018/047714 WO2019040727A1 (en) 2017-08-23 2018-08-23 BINDING PROTEINS FOR NKG2D, CD16 AND ANTIGEN ASSOCIATED WITH A TUMOR

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023027219A Division JP2023062184A (ja) 2017-08-23 2023-02-24 Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍－関連抗原に結合するタンパク質

Publications (2)

Publication Number Publication Date
JP2020531525A true JP2020531525A (ja) 2020-11-05
JP2020531525A5 JP2020531525A5 (enExample) 2021-09-30

Family

ID=65439284

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511319A Ceased JP2020531525A (ja) 2017-08-23 2018-08-23 Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍−関連抗原に結合するタンパク質
JP2023027219A Pending JP2023062184A (ja) 2017-08-23 2023-02-24 Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍－関連抗原に結合するタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023027219A Pending JP2023062184A (ja) 2017-08-23 2023-02-24 Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍－関連抗原に結合するタンパク質

Country Status (13)

Country Link
US (1) US20200231679A1 (enExample)
EP (1) EP3672993A4 (enExample)
JP (2) JP2020531525A (enExample)
KR (1) KR20200038530A (enExample)
CN (1) CN111315778A (enExample)
AU (1) AU2018322178A1 (enExample)
BR (1) BR112020003654A2 (enExample)
CA (1) CA3072919A1 (enExample)
IL (2) IL311488A (enExample)
MX (1) MX2020002036A (enExample)
RU (1) RU2020111554A (enExample)
SG (1) SG11201913968VA (enExample)
WO (1) WO2019040727A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023508942A (ja) * 2020-05-06 2023-03-06 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
CA3090236A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MA53293A (fr) 2018-08-08 2021-11-17 Dragonfly Therapeutics Inc Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
MX2021001527A (es) 2018-08-08 2021-06-15 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
CN115298217A (zh) * 2019-10-15 2022-11-04 蜻蜓疗法股份有限公司 结合nkg2d、cd16及flt3的蛋白质
US20230073946A1 (en) * 2020-01-20 2023-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Affinity peptide conjugated with antioxidant for protection of proteins from oxidation
CN114437214B (zh) * 2020-11-03 2023-06-02 南京北恒生物科技有限公司 靶向lir1的抗体及其用途
EP4273161A4 (en) * 2020-12-31 2025-04-02 Innovent Biologics (Suzhou) Co., Ltd. Protein with heterodimeric antibody FC and manufacturing method therefor
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
WO2025166146A1 (en) * 2024-02-02 2025-08-07 Triveni Bio, Inc. Klk5/7 + ox40 targeting antibodies and uses thereof
WO2025166138A1 (en) * 2024-02-02 2025-08-07 Triveni Bio, Inc. Klk5/7 + tslp targeting antibodies and uses thereof
CN118812708B (zh) * 2024-06-28 2025-04-04 北京普利米特生物科技有限公司 抗il-33抗体或其抗原结合片段及其用途

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038339A1 (en) * 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
JP2009500346A (ja) * 2005-06-29 2009-01-08 ユニバーシティー・オブ・マイアミ 癌処置用の抗体−免疫細胞リガンド融合タンパク質
US7879985B2 (en) * 2007-12-14 2011-02-01 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
JP2013500721A (ja) * 2009-07-29 2013-01-10 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
DE102013019352A1 (de) * 2013-11-13 2015-09-17 Elke Pogge Von Strandmann Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort
US9273136B2 (en) * 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
JP2016514463A (ja) * 2013-03-15 2016-05-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
WO2016207273A2 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific antigen binding proteins
WO2018148566A1 (en) * 2017-02-10 2018-08-16 Adimab, Llc Proteins binding bcma, nkg2d and cd16

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
EP3241561B1 (en) * 2014-03-05 2025-04-30 Autolus Limited Conjugated antibody or bispecific t-cell engager which selectively binds either tcr beta constant region 1 (trbc1) or trbc2
AU2016219785B2 (en) * 2015-02-20 2021-10-28 Ohio State Innovation Foundation Bivalent antibody directed against NKG2D and tumor associated antigens
US20180327499A1 (en) * 2015-11-13 2018-11-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
CA3011535A1 (en) * 2016-01-13 2017-07-20 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
US20200095327A1 (en) * 2017-02-08 2020-03-26 Dragonfly Therapeutics, Inc. Antibody heavy chain variable domains targeting the nkg2d receptor

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038339A1 (en) * 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
JP2009500346A (ja) * 2005-06-29 2009-01-08 ユニバーシティー・オブ・マイアミ 癌処置用の抗体−免疫細胞リガンド融合タンパク質
US7879985B2 (en) * 2007-12-14 2011-02-01 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
US9273136B2 (en) * 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
JP2013500721A (ja) * 2009-07-29 2013-01-10 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
JP2016514463A (ja) * 2013-03-15 2016-05-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
DE102013019352A1 (de) * 2013-11-13 2015-09-17 Elke Pogge Von Strandmann Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
WO2016207273A2 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific antigen binding proteins
WO2018148566A1 (en) * 2017-02-10 2018-08-16 Adimab, Llc Proteins binding bcma, nkg2d and cd16

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol. 12, no. 11, JPN6021051696, 2016, pages 2790 - 2796, ISSN: 0005168278 *
ONCOIMMUNOLOGY, vol. Vol.2, Issue 6, JPN6022035496, 2013, pages 24481, ISSN: 0005168277 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023508942A (ja) * 2020-05-06 2023-03-06 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
JP7512394B2 (ja) 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
JP2024160215A (ja) * 2020-05-06 2024-11-13 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質

Also Published As

Publication number Publication date
US20200231679A1 (en) 2020-07-23
IL272706A (en) 2020-04-30
EP3672993A1 (en) 2020-07-01
CN111315778A (zh) 2020-06-19
CA3072919A1 (en) 2019-02-28
SG11201913968VA (en) 2020-01-30
RU2020111554A (ru) 2021-09-23
JP2023062184A (ja) 2023-05-02
BR112020003654A2 (pt) 2020-11-17
AU2018322178A1 (en) 2020-02-20
IL311488A (en) 2024-05-01
WO2019040727A1 (en) 2019-02-28
MX2020002036A (es) 2020-03-24
KR20200038530A (ko) 2020-04-13
RU2020111554A3 (enExample) 2022-01-19
EP3672993A4 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
JP2023062184A (ja) Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍－関連抗原に結合するタンパク質
US20210261668A1 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
JP7431392B2 (ja) ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質
US20210206859A1 (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
JP2021035388A (ja) Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２、ｃｅａまたはクローディン−１８．２を標的にする多重特異性結合タンパク質
JP2024012297A (ja) Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質
JP2020534269A (ja) Ｎｋｇ２ｄ、ｃｄ１６、およびｃ型レクチン様分子−１（ｃｌｌ−１）に結合するタンパク質
JP2021512630A (ja) Ｎｋｇ２ｄ受容体を標的とする抗体可変ドメイン
JP2022105121A (ja) Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質
KR20190120775A (ko) Cd33, nkg2d 및 cd16에 결합하는 단백질
KR20190115469A (ko) Bcma, nkg2d 및 cd16에 결합하는 단백질
JP2021523913A (ja) Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質
JP2020529410A (ja) Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質
JP2021533159A (ja) Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質
JP2020510644A (ja) Ｇｄ２、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質
WO2018152547A1 (en) Proteins binding cd123, nkg2d and cd16
RU2816716C2 (ru) Белки, связывающие NKG2D, CD16 и опухолеассоциированный антиген
HK40062610A (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240214

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20240621